(Z)-5-([1,1'-biphenyl]-4-ylmethylene)thiazolidine-2,4-dione | 675595-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-5-([1,1'-biphenyl]-4-ylmethylene)thiazolidine-2,4-dione
• 英文别名: (Z)-5-([1,1′-biphenyl]-4-ylmethylene)thiazolidine-2,4-dione；5-Biphenyl-4-ylmethylene-thiazolidine-2,4-dione；(5Z)-5-(biphenyl-4-ylmethylidene)-1,3-thiazolidine-2,4-dione；(5Z)-5-[(4-phenylphenyl)methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 675595-37-6
• 化学式: C₁₆H₁₁NO₂S
• 分子量: 281.335
• InChiKey: RHRLYVRWKISPMD-UVTDQMKNSA-N

物化性质

• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-5-([1,1'-biphenyl]-4-ylmethylene)thiazolidine-2,4-dione 在 盐酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 26.0h， 生成 (Z)-2-(5-(biphenyl-4-ylmethylene)-2,4-dioxothiazolidin-3-yl)acetic acid
  参考文献：
  名称：

  Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors

  摘要：

  The structure-activity relationships (SARs) of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors (ARIs) were extended by varying the substitution pattern on the 5-arylidene moiety and on N-3. In particular, the introduction of an additional aromatic ring or an H-bond donor group on the 5-benzylidene ring enhanced ALR2 inhibitory potency. Moreover, the presence of a carboxylic anionic chain on N-3 was shown to be an important, although not essential, structural requisite to produce high levels of ALR2 inhibition. The length of this carboxylic chain was critical and acetic acids 4 were the most effective inhibitors among the tested derivatives. Molecular docking simulations into the ALR2 active site accorded with the in vitro inhibition data. They allowed the rationalization of the observed SARs and provided a pharmacophoric model for this class of ARIs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.02.026
• 作为产物：
  描述：

  2,4-噻唑烷二酮 、 对苯基苯甲醛 在 C₅H₁₁N 作用下， 以 乙醇 为溶剂， 生成 (Z)-5-([1,1'-biphenyl]-4-ylmethylene)thiazolidine-2,4-dione
  参考文献：
  名称：

  包含2,4-噻唑烷二酮衍生物的非羧酸的合成，诱导对接研究和体外醛糖还原酶抑制活性。

  摘要：

  在继续我们的研究中，我们在这里报告了一系列含有2,4-噻唑烷二酮的非羧酸衍生物，它们是先前合成的羧酸的类似物，我们发现它们在体外是非常有效的醛糖还原酶（ALR2）抑制剂。尽管用羧酰胺或N-羟基羧酰胺取代羧基会降低体外对ALR2的抑制作用，但这导致鉴定出具有微摩尔ALR2亲和力的主要是非电离的衍生物。5-亚芳基部分深刻地影响了这些2，4-噻唑烷二酮的活性。我们的诱导拟合对接研究表明，5-（4-羟基亚苄基）取代的衍生物可能通过去质子化的酚基团结合ALR2活性位点的极性识别区，

  DOI：

  10.1016/j.bmc.2008.04.072

文献信息

• Antileishmanial activity evaluation of thiazolidine-2,4-dione against Leishmania infantum and Leishmania braziliensis
  作者：Flávio Simas Moreira Neri、David Bacelar Costa Júnior、Thamires Quadros Froes、Priscila Brandão Gomes da Silva、Micalyne Soares do Egito、Paulo Otávio Lourenço Moreira、Fernando de Pilla Varotti、Marcelo Santos Castilho、Rafael Gonçalves Teixeira-Neto、Jullianna Ferreira Cavalcanti de Albuquerque、Franco Henrique Andrade Leite

  DOI：10.1007/s00436-020-06706-3

  日期：2020.7

  development of new drugs urgent. To achieve this goal, the integration of kinetic and DSF assays against parasitic validated targets, along with phenotypic assays, can help the identification and optimization of bioactive compounds. Pteridine reductase 1 (PTR1), a validated target in Leishmania sp., is responsible for the reduction of folate and biopterin to tetrahydrofolate and tetrahydrobiopterin, respectively

  利什曼病每年造成约65,000人死亡。尽管有死亡率数据，但可用于治疗患者的药物不足，并且除了严重的不良反应外，还具有中等的治疗功效，这使得开发新药物变得迫在眉睫。为了实现此目标，针对寄生虫验证目标的动力学和DSF分析以及表型分析的集成可以帮助鉴定和优化生物活性化合物。蝶呤还原酶1（PTR1）是利什曼原虫（Leishmania sp。）中经过验证的靶标，负责将叶酸和生物蝶呤分别还原为四氢叶酸和四氢生物蝶呤，这两者对于细胞生长都是必不可少的。除了体外评估16种噻唑烷-2,4-二酮衍生物对利什曼原虫主要PTR1（Lm PTR1），使用差示扫描荧光法（ThermoFluor®），采用表型分析评估化合物对巴西利什曼原虫（MHOM / BR / 75 / M2903）和婴儿利什曼原虫（MHOM / BR / 74 / PP75）的作用）前鞭毛虫的生存能力。ThermoFluor®结果表明，噻唑烷-2,
• Identification of new non-carboxylic acid containing inhibitors of aldose reductase
  作者：Rosanna Maccari、Rosella Ciurleo、Marco Giglio、Mario Cappiello、Roberta Moschini、Antonella Del Corso、Umberto Mura、Rosaria Ottanà

  DOI：10.1016/j.bmc.2010.04.016

  日期：2010.6.1

  Non-carboxylic acid containing bioisosteres of (5-arylidene-2,4-dioxothiazolidin-3-yl)acetic acids, which are active as aldose reductase (ALR2) inhibitors, were designed by replacing the carboxylic group with the trifluoromethyl ketone moiety. The in vitro evaluation of the ALR2 inhibitory effects of these trifluoromethyl substituted derivatives led to the identification of two inhibitors effective

  通过用三氟甲基酮部分取代羧基，设计了作为醛糖还原酶（ALR2）抑制剂具有活性的（5-亚芳基-2,4-二氧噻唑并恶唑烷-3-基）乙酸的非羧酸生物甾醇。这些三氟甲基取代的衍生物对ALR2抑制作用的体外评估导致鉴定出两种在低微摩尔剂量下有效的抑制剂。进一步证实，噻唑烷二酮支架的N-3上的羧基是获得最高功效水平的决定性条件。然而，对于与靶酶的相互作用不是必需的，并且可以被不同的极性基团取代，从而获得较少的离子化或工会化的抑制剂。
• In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications—A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B
  作者：Rosaria Ottanà、Paolo Paoli、Mario Cappiello、Trung Ngoc Nguyen、Ilenia Adornato、Antonella Del Corso、Massimo Genovese、Ilaria Nesi、Roberta Moschini、Alexandra Naß、Gerhard Wolber、Rosanna Maccari

  DOI：10.3390/molecules26020330

  日期：——

  possibility to target both aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands

  糖尿病 (DM) 是一种复杂的疾病，目前影响超过 4.6 亿人，是全球主要的死亡原因之一。它的发展意味着许多代谢功能障碍和高血糖引起的慢性并发症的发生。可以合理设计多种配体用于治疗多因素疾病，例如 DM，其精确目标是同时控制与疾病相关的多种致病机制，并提供比选择性药物组合更有效、更安全的治疗方法。我们之前的研究结果强调了靶向醛糖还原酶 (AR) 和蛋白酪氨酸磷酸酶 1B (PTP1B) 的可能性，这两种酶与 DM 及其并发症的发展密切相关，我们合成了 3-(5-arylidene-4-oxothiazolidin-3-yl) 丙酸和类似的 2-丁烯酸衍生物，目的是平衡双 AR/PTP1B 抑制剂的有效性，我们已将其鉴定为设计的多配体 (DMLs) ）。在测试的化合物中，4f 在低微摩尔浓度下表现出均衡的 AR/PTP1B 抑制作用，以及在鼠 C2C12 细胞培养物中有趣的胰岛素敏化活性。此处强调的
• Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
  申请人：Kaarsholm Niels Christian

  公开号：US20090123563A1

  公开（公告）日：2009-05-14

  Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.

  这段话的中文翻译如下：使用分支配体的新型制备物，用于R-状态胰岛素六聚体的HisB10 Zn2+位点。这些制备物具有长效作用，旨在为灵活的注射方案设计。
• Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors
  作者：Annachiara Gandini、Manuela Bartolini、Daniele Tedesco、Loreto Martinez-Gonzalez、Carlos Roca、Nuria E. Campillo、Josefa Zaldivar-Diez、Concepción Perez、Giampaolo Zuccheri、Andrea Miti、Alessandra Feoli、Sabrina Castellano、Sabrina Petralla、Barbara Monti、Martina Rossi、Fabio Moda、Giuseppe Legname、Ana Martinez、Maria Laura Bolognesi

  DOI：10.1021/acs.jmedchem.8b00610

  日期：2018.9.13

  Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3 beta and tau aggregation process. On the basis of this consideration and on our interest in multitarget paradigms in AD, we report on the discovery of 2,4-thiazolidinedione derivatives endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3 beta, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 ktM, respectively. In addition, they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations. Finally, both compounds were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model. To the best of our knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compounds hitting tau cascade at two different hubs.